Nemolizumab for treating prurigo nodularis [ID6451]

  • In development
  • GID-TA11566
  • Expected publication date: TBC

NICE has paused the evaluation of nemolizumab for treating prurigo nodularis [ID6451] because the company and NHSE have commenced commercial discussions

Documents

Documents created during the development process.

Declaration of interests

Draft guidance

Invitation to participate

Notes